REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Clinical trials for REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy trial offers hope for HIV patients with advanced cancers
Disease control OngoingThis is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…
Matched conditions: REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New drug combo aims to tame tough thyroid cancers
Disease control OngoingThis study is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can help control advanced thyroid cancer that has stopped responding to radioactive iodine and has worsened after one prior targeted therapy. The goal is to see if this three-drug a…
Matched conditions: REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC